Get the full picture
syngo.via is intelligent.
Quantify the invisible.
The software1 delivers powerful quantitative reading functionality for oncology, cardiology and neurology cases and guides you through the workflow.
Clinical Return on Innovation
- Oncology: Reproducible PERCIST metrics for confident therapy response assessment, allowing for early therapy adjustment.
- Neurology: Reproducible SUVratio and database comparison aids PET amyloid exams in providing appropriate diagnostic evaluations and therapy planning.
- Cardiology: Reproducible blood flow in ml/min supports detection of triple vessel disease for possible intervention.
The new syngo.via version VA20 adds features to oncology that complete the quantitative trending workflow: The SUVpeak metric is complemented with automatic detection of liver and blood pool background SUV, providing PET response criteria in solid tumors (PERCIST). Second, the new trending graph capability plots quantification metrics over time for quick visual therapy response assessment — a great addition to the display of up to eight time points and the quantification table. Together with the reproducible quantification capabilities of Biograph mCT, follow-up studies can now be evaluated with confidence. Further, dynamic studies can be evaluated with time activity curves.
syngo.PET Dynamic Analysis
Graphs radiopharmaceutical uptake over time (time activity curve) via SUV-based quantification of volumetric regions of interest, using metrics such as SUVmax, SUVpeak and SUVmean.
Allows for SUV-based volumetric segmentation. Automatically provides volume, RECIST, SUVpeak, SUVmax and other metrics. Complete implementation of the PERCIST standardised response criteria for PET, incl. automatic placement of PERCIST reference regions.
Provides a comprehensive set of sophisticated layouts specifically designed for reading general nuclear medicine cases. The application automatically selects the most appropriate layout based upon the available data.
This application provides advanced features for faster, simpler oncological reading. It supports the automated segmentation and evaluation of lesions in the lungs, liver, lymph nodes and other organs – providing standardized quantification in RECIST (1.0 & 1.1), WHO and volume as well as Choi criteria and Advanced HU Statistics.
syngo.PET&CT Cross-Timepoint Evaluation
This application allows you to assess changes in tumor activity and size across four points in time, by comparing quantitative analysis of volume, RECIST, WHO, and minimum, average and maximum functional uptake.
syngo.PET&CT Onco Multi-Timepoint
Increases the number of time points that can be displayed at the same time in a single layout in fully synchronized view from four to eight.
syngo.PET&CT Therapy Interface
Publish Gross Tumor Volumes (GTV) contours as DICOM RT Structure Sets for use in radiation therapy planning. Convert diagnostic regions of interest such as PET iso-contours and PET and CT segmentatio ns into Gross Tumor Volumes (GTV) and visualize GTV contours over planning CT and other relevant volumes via fused segments.
Quantitative assessment of amyloid PET studies with SUVr are further enhanced in VA20 with a dedicated amyloid normals database. With a clear dedication to quantitative assessments, VA20 further offers the opportunity to create custom normal databases to match an institution’s patient population. Biograph mCT’s finest volumetric resolution2 of 87mm3, based on 400x400 matrix recon, and Neuro AC capabilities match the requirements for the quantitative assessment of amyloid scans.
syngo.MI Neuro Database Creation
Enables users to create and manage custom normal databases for any PET or SPECT neurology study to match site specific patient population and protocol needs. Patients can be easily added to custom databases during the normal workflow.
syngo.PET Amyloid Plaque3
Complements the qualitative visual interpretation of PET amyloid scans with quantitative information. It identifies six key brain regions with characteristic PET signal in diseased patients by registering to a template brain scan. SUV ratios are automatically computed for comparison against published thresholds. Also includes a PET amyloid normal database.
syngo.PET Neuro Database Comparison
Enables automated registration and fusion of PET studies with CT and MR. The application supports automated spatial normalization and 3D ROI placement, Voxel and 3D ROI-based quantification of neuroglucose metabolism (PET: FDG).
syngo.SPECT Neuro Database Comparison3
Provides physicians with information about the degree of deviation of a patient exam from the normal database, in standard deviations. Normal databases for SPECT are available for ECD and HMPAO.
syngo.SPECT Striatal Analysis
Enhances the syngo.via MI Neurology workflows by supporting comprehensive striatal evaluations for the assessment of movement disorders, especially Parkinson’s disease. It makes it possible to conduct symmetry evaluations and comparisons to a reference region based on DatScan studies.
syngo.CT Neuro DSA
(Digital Subtraction Angiography)
This dedicated post-processing application allows you to remove bone structures from CT Angiography (CTA) data sets in order to improve visualization of the cerebral vasculature. This enhances visualization of vascular structures in the area of the skull and helps to delineate aneurysms and other vascular diseases.
syngo.CT Neuro Perfusion
This application visualizes blood perfusion in the brain. In the case of ischemic stroke, it can help estimate the size of the core infarct and the extent of tissue at risk of infarction (penumbra) that could potentially be salvaged with further treatment.
For cardiology, VA20 introduces the hybrid coronary view. A correlative view of stenotic areas on the CTA together with any hemodynamic impact based on PET results can be displayed. Myocardial surface projections can be selected from quantitative parameters including perfusion, blood flow, flow reserve, wall thickening and wall motion. Combined with the SMART Cardiac registration and single injection blood flow capabilities of Biograph mCT, a comprehensive solution for routine quantitative cardiac assessment is now available.
syngo.CT Extension Corridor4DM
An extension available for syngo.PET Corridor4DM and syngo.SPECT Corridor4DM. It enables volumetric registration of hybrid or stand-alone CT to PET and SPECT.
syngo.MI Hybrid Coronary View
Enables interactive fused VRT display of PET or SPECT quantification results with CT coronary angiography. PET or SPECT quantification results can be selected as stress or rest perfusion, reversibility, stress or rest blood flow and coronary flow reserve.
Offers full access to the Invia Corridor 4DM PET suite for assessment of PET perfusion scans.
syngo.PET Extension Corridor4DM CFR
Optional extension to syngo.PET Corridor4DM. Adds Coronary Flow Reserve (CFR) using the GFADS algorithm.
syngo.PET Myocardial Blood Flow
Enables physicians to review relative perfusion results together with myocardial blood flow in ml/min and flow reserve in a single application, and supports both rubidium and ammonia tracers.
State-of-the-art software for the quantification, review, and reporting of cardiac perfusion, function and anatomy. It includes transient ischemic dilation (TID), myocardial function incl. LV volumes and EF, regional wall thickening, motion, and time to peak contractility. It provides databases for assessment of FDG distribution and viability.
syngo.CT Cardiac Function
This application allows you to read and diagnose CT images of the heart in order to evaluate left ventricular function. As a result, it is now possible to complete a full cardiac assessment in less than four minutes.
This workflow step quantifies coronary calcifications (mass, volume, Agatston score) and calculates the patient's coronary age. During the evaluation, the patient's score is compared to the scores of a healthy reference group, e.g. the MESA study.
syngo.CT Coronary Analysis
This function provides a cardiac-specific set of automatic pre-processing steps and display functions, in order to rapidly and reliably evaluate and quantify angiography images of the coronary arteries - making it possible to rule out coronary artery disease in less than a minute.
1syngo.via can be used as a stand-alone device or together with a variety of syngo.via-based software options which are medical devices in their own right.
2Based on competitive literature available at time of publication. Data on file.
3It is intended for use only with approved amyloid radiopharmaceuticals in the country of use. Users should review the drug labeling for approved uses.